Commercial insurance coverage of blockbuster GLP-1 drugs has not expanded much over the past year, despite growing demand and expanded indications, according to a new report from GoodRx. Data from ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

As weight loss drugs continue to grow in popularity in the U.S., some health leaders are warning about fake drugs on the ...

Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...

Imagine being one of the millions of Americans in need of a hip or knee replacement due to osteoarthritis. Severe pain, reduced physical activity, an inability to perform many routine ...

A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration ...

Class A shares of the Alger Focus Equity Fund outperformed the Russell 1000 Growth Index during the fourth quarter of 2024.

Class A shares of the Alger Spectra Fund outperformed the Russell 3000 Growth Index during the fourth quarter of 2024. Read ...